Join Growin Stock Community!

Assertio holdings, inc.ASRT.US Overview

US StockHealthcare
(No presentation for ASRT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ASRT AI Insights

ASRT Overall Performance

ASRT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ASRT Recent Performance

0.44%

Assertio holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ASRT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ASRT Key Information

ASRT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ASRT Profile

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Price of ASRT

ASRT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ASRT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.51
PE Ratio (TTM)
-
Forward PE
3375523581187926528.00
PS Ratio (TTM)
0.54
PB Ratio
0.73
Price-to-FCF
5.64
METRIC
VALUE
vs. INDUSTRY
Gross Margin
68.16%
Net Margin
-21.06%
Revenue Growth (YoY)
9.21%
Profit Growth (YoY)
5.88%
3-Year Revenue Growth
13.07%
3-Year Profit Growth
5.84%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.51
PE Ratio (TTM)
-
Forward PE
3375523581187926528.00
PS Ratio (TTM)
0.54
PB Ratio
0.73
Price-to-FCF
5.64
Gross Margin
68.16%
Net Margin
-21.06%
Revenue Growth (YoY)
9.21%
Profit Growth (YoY)
5.88%
3-Year Revenue Growth
13.07%
3-Year Profit Growth
5.84%

  • When is ASRT's latest earnings report released?

    The most recent financial report for Assertio holdings, inc. (ASRT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ASRT's short-term business performance and financial health. For the latest updates on ASRT's earnings releases, visit this page regularly.

  • What is the operating profit of ASRT?

    According to the latest financial report, Assertio holdings, inc. (ASRT) reported an Operating Profit of 11.2M with an Operating Margin of 22.65% this period, representing a growth of 507.64% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ASRT's revenue growth?

    In the latest financial report, Assertio holdings, inc. (ASRT) announced revenue of 49.46M, with a Year-Over-Year growth rate of 69.36%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ASRT have?

    At the end of the period, Assertio holdings, inc. (ASRT) held Total Cash and Cash Equivalents of 38.5M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ASRT go with three margins increasing?

    In the latest report, Assertio holdings, inc. (ASRT) achieved the “three margins increasing” benchmark, with a gross margin of 72.4%%, operating margin of 22.65%%, and net margin of 23.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ASRT's profit trajectory and future growth potential.

  • Is ASRT's EPS continuing to grow?

    According to the past four quarterly reports, Assertio holdings, inc. (ASRT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.12. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ASRT?

    Assertio holdings, inc. (ASRT)'s Free Cash Flow (FCF) for the period is -4.77M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 13,520% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.